ZYUS Life Sciences CorporationZYUS.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · zyus.com
ZYUS Life Sciences Corporation is a Canadian life sciences company focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company holds multiple Health Canada licenses including a Cannabis Drug License, and operates a pharmaceutical-grade cannabinoid formulation facility in Saskatoon, Saskatchewan, pursuing non-opioid-based pharmaceutical solutions.
Key ratios
FCF / Sales
-2309.5%TTM
2024
-2062.8%2023
-5193.4%2022
-3400.7%
ROA
-41.0%TTM
2024
-35.1%2023
-22.8%2022
-15.5%
ROE
-3516.8%TTM
2024
-380.5%2023
-305.8%2022
-164.8%
Revenue growth
2.9%TTM
2024
37.0%2023
17.8%2022
44.0%
Recent news
ZYUS Life Sciences Announces Closing of First Tranche of Non-Brokered Unit Offering Private Placement
ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced Cancer
ZYUS Life Sciences Corporation Announces Planned Release Date for Phase 2a Clinical Trial Results, Annual General Meeting Results and Change in Audit Committee Chair
ZYUS Life Sciences Corporation Provides General Business Update and Announces Changes in Executive Leadership
ZYUS Life Sciences Announces Closing of Debt Financing
ZYUS Life Sciences Corporation Provides Liquidity and Working Capital Update and Announces Reinstatement to Trading
ZYUS Life Sciences Corporation Announces Completion of Secured Loan Financing
ZYUS Life Sciences Corporation Announces Closing of Eighth Tranche of Secured Loan Financing and Amendment to Unsecured Promissory Note
ZYUS Life Sciences Announces Closing of Seventh Tranche of Secured Loan Financing
ZYUS Life Sciences Corporation Announces Revocation of Failure-to-File Cease Trade Order
Track ZYUS.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer